Fund Insights
Common Fund Bets
See what stocks and ETFs funds are collectively bullish/bearish on
Largest Fund Trades
Explore the largest stock and ETF buys and sells made by funds
High Conviction Trades
Discover high conviction trades that caused a significant change in a fund's stake in a stock
Fund Manager Portfolios
Gain insights from the world’s largest funds and super investors
Analyst Insights
Price Target Consensus
See what stocks research analysts are collectively bullish/bearish on
Latest Ratings Feed
Explore the latest ratings and price targets from the best equity research analysts
Equity Analyst Profiles
Browse analysts, their latest ratings and track record
Research Firm Profiles
Browse research firm recommendations, trends, and performance
WSR Indexes
Fund Manager Index
Stock index based on fund manager consensus updated each quarter
Analyst Index
COMING SOON - Stock index based on equity analyst consensus updated every second
Search
Sign in
Sign up
BioMarin Pharmaceuticals
BMRN
Market cap
$10.8B
Overview
Fund Trends
Analyst Outlook
Journalist POV
56.08
USD
+0.88
1.59%
At close
Updated
Jan 14, 4:00 PM EST
Pre-market
After hours
56.44
+0.36
0.64%
1D
5D
1M
3M
6M
YTD
1Y
5Y
10Y
1 day
1.59%
5 days
-8.07%
1 month
7.6%
3 months
6.88%
6 months
-3.69%
Year to date
-5.67%
1 year
-12.11%
5 years
-31.07%
10 years
-33.58%
Upgrade to unlock
Positive
Neutral
Negative
Sentiment
3-Months
Positive
Neutral
37.1%
Negative
Positive
Neutral
Negative
Positive
Zacks Investment Research
21 hours ago
4 Value Stocks to Buy As Wall Street Weighs Trump Policies
As markets reel from policy uncertainty, UHS, PNC, GPN, and BMRN emerge as compelling value picks with strong cash flow.
Positive
Zacks Investment Research
yesterday
BMRN or TARS: Which Is the Better Value Stock Right Now?
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with BioMarin Pharmaceutical (BMRN) and Tarsus Pharmaceuticals, Inc. (TARS). But which of these two stocks is more attractive to value investors?
Positive
Zacks Investment Research
yesterday
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Positive
Zacks Investment Research
yesterday
Is BioMarin Pharmaceutical (BMRN) a Great Value Stock Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Neutral
Seeking Alpha
2 days ago
BioMarin Pharmaceutical Inc. (BMRN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
BioMarin Pharmaceutical Inc. (BMRN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral
PRNewsWire
2 days ago
BioMarin Appoints Arpit Davé Chief Digital and Information Officer
Mr. Davé Brings more than 20 Years of Experience in Creating Enterprise Value through Digital Transformation, Information Technology and Artificial Intelligence across the Biopharmaceutical Industry SAN RAFAEL, Calif., Jan. 12, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced it has appointed Arpit Davé as Executive Vice President, Chief Digital and Information Officer, a new position reporting directly to President and Chief Executive Officer Alexander Hardy.
Positive
Zacks Investment Research
2 days ago
Why BioMarin Pharmaceutical (BMRN) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Neutral
PRNewsWire
6 days ago
BioMarin to Present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, at 11:15 am PT / 2:15 pm ET, in San Francisco, CA
SAN RAFAEL, Calif., Jan. 8, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will present at the 44th Annual J.P.
Neutral
PRNewsWire
6 days ago
Veeva and BioMarin Form Long-Term Strategic Partnership
Partnership to help BioMarin increase speed and efficiency in developing and commercializing innovative therapies PLEASANTON, Calif., and SAN RAFAEL, Calif.
Positive
The Motley Fool
10 days ago
10 Magnificent Stocks That Can Make You Richer in 2026
The stock market's major indexes delivered, once again, with the Dow Jones Industrial Average, S&P 500, and Nasdaq Composite all climbing to record highs in 2025. Regardless of whether the bull market continues or a bear market takes shape, 10 sensational businesses are ideally positioned to make investors money.
Show more
See News Rankings
Sign up
Sign in
Fund Insights
Common Fund Bets
See what stocks and ETFs funds are collectively bullish/bearish on
Largest Fund Trades
Explore the largest stock and ETF buys and sells made by funds
High Conviction Trades
Discover high conviction trades that caused a significant change in a fund's stake in a stock
Fund Manager Portfolios
Gain insights from the world’s largest funds and super investors
Analyst Insights
Price Target Consensus
See what stocks research analysts are collectively bullish/bearish on
Latest Ratings Feed
Explore the latest ratings and price targets from the best equity research analysts
Equity Analyst Profiles
Browse analysts, their latest ratings and track record
Research Firm Profiles
Browse research firm recommendations, trends, and performance
WSR Indexes
Fund Manager Index
Stock index based on fund manager consensus updated each quarter
Analyst Index
COMING SOON - Stock index based on equity analyst consensus updated every second
Theme
Close